SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

diaDexus, Inc. – ‘8-K’ for 11/12/03

On:  Wednesday, 11/12/03, at 5:15pm ET   ·   For:  11/12/03   ·   Accession #:  1169232-3-6538   ·   File #:  0-26483

Previous ‘8-K’:  ‘8-K’ on 10/24/03 for 10/23/03   ·   Next:  ‘8-K’ on 11/18/03 for 11/14/03   ·   Latest:  ‘8-K’ on 4/29/16 for 4/28/16

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

11/12/03  diaDexus, Inc.                    8-K:5,7    11/12/03    2:9K                                     Edgar Ease Svc Bureau/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         3      8K 
 2: EX-99.1     Miscellaneous Exhibit                                  3     12K 


8-K   —   Current Report
Document Table of Contents

Page (sequential) | (alphabetic) Top
 
11st Page   -   Filing Submission
2Item 5. Other Events and Regulation FD Disclosure
"Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
8-K1st Page of 3TOCTopPreviousNextBottomJust 1st
 

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2003 VAXGEN, INC. (Exact name of Registrant as Specified in its Charter) DELAWARE 0-26483 94-3236309 (State or other jurisdiction of (Commission File Number) (I.R.S. Employer incorporation or organization) Identification Number) 1000 MARINA BLVD., SUITE 200 BRISBANE, CALIFORNIA 94005 (Address of Principal Administrative Offices) Registrants Telephone Number, Including Area Code: (650) 624-1000
8-K2nd Page of 3TOC1stPreviousNextBottomJust 2nd
Item 5. Other Events and Regulation FD Disclosure. On November 12, 2003, VaxGen, Inc. issued a press release entitled, "VaxGen Announces Results of its Phase III HIV Vaccine Trial in Thailand: Vaccine Fails to Meet Endpoints". This press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. (c) Exhibits. Exhibit No. Description 99.1 Press release dated November 12, 2003, entitled, "VaxGen Announces Results of its Phase III HIV Vaccine Trial in Thailand: Vaccine Fails to Meet Endpoints".
8-KLast Page of 3TOC1stPreviousNextBottomJust 3rd
SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VaxGen, Inc. (Registrant) Dated: November 12, 2003 By: /s/ Carter A. Lee ------------------------------ Carter Lee Senior Vice President Finance & Administration

Dates Referenced Herein   and   Documents Incorporated by Reference

Referenced-On Page
This ‘8-K’ Filing    Date First  Last      Other Filings
Filed on / For Period End:11/12/0313None on these Dates
 List all Filings 
Top
Filing Submission 0001169232-03-006538   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 1:14:10.1pm ET